Henry Schein, Inc. (NASDAQ:HSIC) reported an EPS of $1.15, beating the estimated $1.11 and marking a 3.60% earnings surprise.
The company’s revenue for Q1 2025 was $3.17 billion, missing the estimated $3.22 billion due to decreased demand for dental products.
HSIC’s financial metrics reveal a P/E ratio of 20.79 and a debt-to-equity ratio of 0.85, indicating investor confidence and a balanced financing approach.
Henry Schein, Inc. (NASDAQ:HSIC) is a leading distributor of medical supplies, serving healthcare professionals worldwide. The company offers a wide range of products, including dental, medical, and veterinary supplies. Despite its strong market presence, HSIC faces competition from other major players in the industry, such as McKesson Corporation and Cardinal Health.
On May 5, 2025, HSIC reported earnings per share (EPS) of $1.15, exceeding the estimated $1.11. This marks a 3.60% earnings surprise, as highlighted by Zacks Investment Research. The company has consistently surpassed consensus EPS estimates in three of the last four quarters, demonstrating its ability to manage costs and improve profitability.
However, HSIC’s revenue for the first quarter of 2025 was approximately $3.17 billion, falling short of the estimated $3.22 billion. This 1.84% shortfall is attributed to a decrease in demand for dental products, impacted by rising inflation. Despite this, the revenue figure remains consistent with the same period last year, indicating stable sales performance.
The company’s financial metrics provide further insight into its valuation. HSIC has a price-to-earnings (P/E) ratio of 20.79, suggesting that investors are willing to pay $20.79 for every dollar of earnings. The price-to-sales ratio is 0.62, meaning investors pay 62 cents for each dollar of sales. These figures reflect investor confidence in the company’s earnings potential.
HSIC maintains a moderate debt-to-equity ratio of 0.85, indicating a balanced approach to financing. The current ratio of 1.42 suggests that the company has sufficient liquidity to cover short-term liabilities. With an enterprise value to operating cash flow ratio of 12.50, HSIC is valued at 12.5 times its operating cash flow, highlighting its strong cash generation capabilities.
